CORRECTING and REPLACING Takeda Provides Further Information about Its New Business Venture with Teva

OSAKA, Japan & JERUSALEM–(BUSINESS WIRE)–Insert after fifth paragraph, first sentence of release: The new business venture will be instantly accretive to Teva’s non GAAP EPS in 2016 and beyond. The corrected release reads: TAKEDA PROVIDES FURTHER INFORMATION ABOUT ITS NEW BUSINESS VENTURE WITH TEVA Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement regarding the overview of their new
Source: BusinessWire-Primary
{inline_image}